secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2025-01-03T23:59:59+00:00
Accession:  0001640334-25-000009
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria Bioscience enters new exec agreement with President/CSO Docherty; base salary, 50% bonus, 15-mo severance
--------------------------------------------------------------------------------

- New agreement effective Jan 1, 2025, replaces prior 2022 pact; Docherty remains President and Chief Scientific Officer.
- Base salary subject to 5% annual increases on Jan 1, 2026 and Jan 1, 2027; performance bonuses up to 50% of base.
- Change of control: up to 24 months base salary plus 2% of affiliate sale value, payable within 90 days.
- Severance without cause or for good reason: 15 months base salary, increasing by 1 month per additional year to max 24 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033425000009/0001640334-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033425000009/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer